GlassScriptPhysician profile
Thomas R Traylor
NPI 1144223447
$468.58
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $21.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $122.22 | 2019 | |
| Olympus America INC. | $71.53 | 2019 | |
| Hologic Sales and Service, LLC | $54.27 | 2019 | |
| Merck Sharp & Dohme LLC | $42.93 | 2019 | |
| Abbvie INC. | $36.07 | 2019 | |
| Daiichi Sankyo INC. | $31.10 | 2019 | |
| Duchesnay USA Incorporated | $29.57 | 2019 | |
| Therapeuticsmd, INC. | $26.69 | 2019 | |
| Roche Diagnostics Corporation | $21.00 | 2020 | |
| Astellas Pharma US INC | $18.12 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Traylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.